TY - JOUR T1 - The Novel CA IX Inhibition Antibody chKM4927 Shows Anti-tumor Efficacy <em>In Vivo</em> JF - Anticancer Research JO - Anticancer Res SP - 1997 LP - 2004 VL - 35 IS - 4 AU - AYAMI YAMAGUCHI AU - KATSUAKI USAMI AU - MUNETAKE SHIMABE AU - KAZUMASA HASEGAWA AU - MASAO ASADA AU - KAZUHIRO MOTOKI AU - TOMOYUKI TAHARA AU - KAZUHIRO MASUDA Y1 - 2015/04/01 UR - http://ar.iiarjournals.org/content/35/4/1997.abstract N2 - Carbonic anhydrase IX (CA IX) is an attractive target for cancer therapy. Many anti-CA IX antibodies have been reported but few have been shown to possess inhibition activity. Furthermore, effective use of CA IX-inhibition antibodies for cancer immunotherapy has not been well-validated since data are mainly limited to in vitro assays. In this study, we established that chKM4927, an anti-CA IX chimeric antibody, recognizes CA IX and has CA IX-specific inhibition activity. ChKM4927 also retains antibody-dependent cellular cytotoxicity (ADCC) activity against CA IX-expressing cancer cells. Compared to controls, chKM4927 treatment (10 mg/kg) showed anti-tumor activity in the VMRC-RCW xenograft model in vivo. ChKM4927-attenuated ADCC activity showed equally effective anti-tumor activity. These results suggest that the CA IX-inhibition antibody chKM4927 has an anti-tumor effect in the VMRC-RCW xenograft model via an ADCC-independent mechanism. ER -